<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We assessed the effects of vildagliptin, a novel dipeptidyl peptidase IV inhibitor, on postprandial <z:chebi fb="23" ids="18059">lipid</z:chebi> and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> metabolism in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>SUBJECTS, MATERIALS AND METHODS: This was a single-centre, randomised, double-blind study in drug-naive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients received vildagliptin (50 mg twice daily, n=15) or placebo (n=16) for 4 weeks </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="17855">Triglyceride</z:chebi>, cholesterol, <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>, <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin, glucagon and glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) responses to a fat-rich mixed meal were determined for 8 h postprandially before and after 4 weeks of treatment </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Relative to placebo, 4 weeks of treatment with vildagliptin decreased the AUC(0-8h) for total trigyceride by 22+/-11% (p=0.037), the incremental AUC(0-8h) (IAUC(0-8h)) for total <z:chebi fb="0" ids="17855">triglyceride</z:chebi> by 85+/-47% (p=0.065), the AUC(0-8h) for chylomicron <z:chebi fb="0" ids="17855">triglyceride</z:chebi> by 65+/-19% (p=0.001) and the IAUC(0-8h) for chylomicron <z:chebi fb="0" ids="17855">triglyceride</z:chebi> by 91+/-28% (p=0.002) </plain></SENT>
<SENT sid="5" pm="."><plain>This was associated with a decrease in chylomicron <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B-48 (AUC(0-8h), -1.0+/-0.5 mg l(-1) h, p=0.037) and chylomicron cholesterol (AUC(0-8h), -0.14+/-0.07 mmol l(-1) h, p=0.046) </plain></SENT>
<SENT sid="6" pm="."><plain>Consistent with previous studies, 4 weeks of treatment with vildagliptin also increased intact GLP-1, suppressed inappropriate glucagon secretion, decreased fasting and postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi>, and decreased HbA(1c) from a baseline of 6.7% (change, -0.4+/-0.1%, p&lt;0.001), <z:hpo ids='HP_0000001'>all</z:hpo> relative to placebo </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: Treatment with vildagliptin for 4 weeks improves postprandial plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B-48-containing <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> particle metabolism after a fat-rich meal </plain></SENT>
<SENT sid="8" pm="."><plain>The mechanisms underlying the effects of this dipeptidyl peptidase IV inhibitor on postprandial <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism remain to be explored </plain></SENT>
</text></document>